BI 836826

Drug Profile

BI 836826

Alternative Names: BI-836826

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Gilead Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD37 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Chronic lymphocytic leukaemia
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Jul 2017 Gilead Sciences terminates a phase Ib/II trial for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02538614)
  • 20 Jul 2017 Boehringer Ingelheim re-initiates enrolment in a phase I trial in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in South Korea (IV) (NCT01403948)
  • 10 Jul 2017 Boehringer Ingelheim completes a phase I trial in Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater, Late-stage disease) in France, Belgium, Germany (NCT01296932)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top